Skip to main content

Taysha Gene Therapies, Inc.

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

TSHA$4.28-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Power of Attorney (included on signature page)

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean Nolan and Kamran Alam, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Taysha Gene Therapies, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Sean NolanChief Executive Officer and Director(Principal Executive Officer)March 19, 2026
Sean Nolan
/s/ Kamran AlamChief Financial Officer(Principal Financial Officer and PrincipalAccounting Officer)March 19, 2026
Kamran Alam
/s/ Phillip B. DonenbergDirectorMarch 19, 2026
Phillip B. Donenberg
/s/ Sean StalfortDirectorMarch 19, 2026
Sean Stalfort
/s/ Sukumar Nagendran, M.D.DirectorMarch 19, 2026
Sukumar Nagendran, M.D.
/s/ Alison Long, M.D., Ph.D.DirectorMarch 19, 2026
Alison Long, M.D., Ph.D.
/s/ Laura Sepp-Lorenzino, Ph.D.DirectorMarch 19, 2026
Laura Sepp-Lorenzino, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.